Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385229 | 0.64 | CA12 (0.36) | LMNAKDM4EALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL3729598 | 0.64 | P2RX4 (0.41) | LMNAALDH1A1CYP3A4SMN1; SMN2POLB | |
| SCHEMBL11513016 | 0.62 | POLB (0.32) | POLBCYP2D6CYP2C9CYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL5956525 | 0.61 | LMNA (0.37) | LMNAKDM4EALDH1A1CYP3A4RECQL | |
| Hydrochloric Acid SCHEMBL5956495 | 0.61 | LMNA (0.37) | LMNAKDM4EALDH1A1CYP3A4RECQL | |
| Bromide SCHEMBL2149556 | 0.61 | LMNA (0.37) | LMNAKDM4EALDH1A1CYP3A4RECQL | |
| Hydrochloric Acid SCHEMBL2150060 | 0.61 | LMNA (0.37) | LMNAKDM4EALDH1A1CYP3A4RECQL | |
| SCHEMBL24116747 | 0.61 | CYP2D6 (0.40) | LMNAGAAKDM4EALDH1A1CYP3A4 | |
| SCHEMBL11831221 | 0.59 | ACE (0.36) | POLBCYP2D6CYP2C9CYP2C19KMT2A | |
| SCHEMBL6887301 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039502-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 AND METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS | UNM RAINFOREST INNOVATIONS | 2023-02-09 | — | — | US | disclosed |
| WO-2021041107-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 | UNM RAINFOREST INNOVATIONS (US) | 2021-03-04 | — | — | WO | disclosed |
| US-8487100-B2 | Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | STC.UNM (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | STC. UNM (US) | 2011-04-21 | — | — | US | disclosed |
| US-7875721-B2 | Modulators of estrogen receptor alpha/beta G protein-coupled receptor 30, e.g., 1-(4-(6-Bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl)1-ethanone; treating diseases such as cancer, neurodegenerative disorders, obesity, osteoporosis, and symptoms of menopause | STC.UNM (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | ARROWHEAD CENTER, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2007019180-A2 | COMPOUNDS FOR BINDING TO ERALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | SCIENCE & TECHNOLOGY CORPORATION @ UNM (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039502-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 AND METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS | GPER1, GPR35, GPR34 | LMNA 2989/4885GAA 2458/4885KDM4E 4702/4885 |
| US-20110092533-A1 | COMPOUNDS FOR BINDING TO ER ALPHA/BETA AND GPR30, METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS AND IDENTIFICATION THEREOF | GPER1, ESR2, ESRRG | LMNA 2955/4885GAA 2721/4885KDM4E 4658/4885 |
| US-20080167334-A1 | Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof | GPER1, ESR2, ESRRG | LMNA 3134/4885GAA 2783/4885KDM4E 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.